Literature DB >> 12008669

The fate of low grade dysplasia in ulcerative colitis.

Thomas A Ullman1, Edward V Loftus, Sanjay Kakar, Lawrence J Burgart, William J Sandborn, William J Tremaine.   

Abstract

OBJECTIVE: The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described.
METHODS: We reviewed the Mayo Clinic records of patients with UC found to have flat LGD between 1990 and 1993 in whom a nonoperative strategy was pursued for 2 months or more.
RESULTS: Eighteen patients with UC and LGD were observed for a median of 32 months. Nine of 18 patients identified with UC and LGD developed advanced neoplastic lesions during follow-up, which were defined as adenocarcinoma, raised dysplasia, or high grade dysplasia. The cumulative incidence of progression to an advanced lesion was 33% at 5 yr (95% CI = 9-56%). Only one patient developed adenocarcinoma, diagnosed 74 months after his initial finding of LGD and 20 months after his last surveillance exam. Besides this patient, adenocarcinoma was not detected in the colectomy specimens of 13 other patients who underwent surgery. Colectomies were performed for dysplasia or cancer in seven patients, active colitis in five patients, and unknown reasons in two patients. Four patients did not have colectomies.
CONCLUSIONS: Neoplastic progression in patients with UC and LGD is common. Total proctocolectomy should be offered to all patients with flat LGD. Our study illustrates numerous pitfalls in the practice of surveillance.

Entities:  

Mesh:

Year:  2002        PMID: 12008669     DOI: 10.1111/j.1572-0241.2002.05610.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  Antagonist: Early surgical intervention in ulcerative colitis.

Authors:  M A Kamm
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

2.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 3.  The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance.

Authors:  Martin S Friedlich; Maha Guindi; Hartley S Stern
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

4.  Epidermal growth factor receptor inhibits colitis-associated cancer in mice.

Authors:  Philip E Dubé; Fang Yan; Shivesh Punit; Nandini Girish; Steven J McElroy; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

Review 5.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 6.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

7.  Current management of inflammatory bowel disease and colorectal cancer.

Authors:  Mark C Mattar; Denver Lough; Michael J Pishvaian; Aline Charabaty
Journal:  Gastrointest Cancer Res       Date:  2011-03

8.  Low-Grade Colorectal Dysplasia and the Need for Colectomy.

Authors:  Thomas A Ullman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

9.  Colorectal cancer in inflammatory bowel disease.

Authors:  Jonathan Potack; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2008-09-30       Impact factor: 4.519

Review 10.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.